Researchers have developed next-generation rifamycin analogs that effectively kill both replicating and nonreplicating Mycobacterium abscessus while minimizing drug-drug interactions. Lead candidates UMN-120 and UMN-121 showed superior efficacy to current treatments in mouse models and retained potency against M. tuberculosis.